Minocycline leads to improved outcomes in a mouse model of atherosclerosis (Shahzad et al., 2011), the transgenic APP/presenilin mouse model of Alzheimer's disease (Biscaro et al., 2012), the MPTP mouse model of Parkinson disease (Du et al., 2001) and after whole‐body γ‐irradiation in mice (Mehrotra et al., 2013) to name a few. Here, APP is linked to Parkinson disease.